EHEsraa Mamdouh Hashem

Esraa Mamdouh Hashem

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Esraa Mamdouh Hashem has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multi-omics integration uncovers epigenetic control of metabolic reprogramming in triple-negative breast cancer

    by Esraa M Hashem, Mai S. Mabrouk

    Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by the absence of estrogen, progesterone, and HER2 receptors, limiting effective targeted therapies. Increasing evidence suggests that metabolic reprogramming, a hallmark of TNBC progression, is driven by underlying epigenetic mechanisms such as DNA methylation. The represented study performed an integrative analysis of transcriptomic (RNA-seq) and methylome data to uncover the metabolic–epigenetic interplay in TNBC. Differential gene expression analysis using DESeq2 revealed significant dysregulation of key metabolic genes, including upregulation of genes encoding glycolytic and serine biosynthesis enzymes and downregulation of metabolic tumor suppressors. Genome-wide methylation profiling identified extensive cytosine–phosphate–guanine (CpG) hypermethylation events associated with transcriptional repression, particularly in promoter regions. Integrative analysis pinpointed a subset of metabolism-related genes exhibiting both differential expression and methylation, such as FBP1 , RASSF1A , and PHGDH . Pathway enrichment analysis highlighted aberrations in glycolysis/gluconeogenesis, fatty acid metabolism, and one-carbon pathways (adjusted p < 0.01). Importantly, TNBC patients with hypermethylated metabolic gene signatures displayed significantly shorter overall survival (log-rank p < 0.05). These findings reveal that DNA methylation-driven metabolic dysregulation contributes to TNBC aggressiveness and may provide novel biomarkers and therapeutic targets at the metabolic–epigenetic interface.

  • Open Access

    Advancing liver cancer diagnosis and treatment with multi-omics approaches: a systematic review

    by Esraa M. Hashem, Ayat M. Karrar, Mai S. Mabrouk

    Hepatocellular carcinoma (HCC), the most prevalent form of liver cancer, remains a major global health concern due to challenges in early detection and limited treatment options. Multi-omics technologies—such as genomics, proteomics, and metabolomics—enable comprehensive insights into the disease’s molecular complexity. This systematic review explores how these approaches contribute to biomarker discovery, molecular classification, and personalized treatment in HCC research. Methods: We conducted a structured review of 32 eligible studies, categorizing their computational methodologies into five primary analytical frameworks: survival analysis, unsupervised clustering, supervised machine learning, differential expression analysis, and pathway/network analysis. Notably, unsupervised clustering and supervised machine learning approaches, such as support vector machines, random forests, and deep learning models, were frequently used for subtype classification, feature selection, and predictive modeling. Results: The review identified that multi-omics approaches are widely used to discover biomarkers, classify HCC subtypes, and predict treatment responses. Common methods include clustering and machine learning. However, clinical validation remains limited, highlighting a gap in translational applicability. Conclusion: From a clinical perspective, multi-omics integration coupled with machine learning holds immense potential for improving early diagnosis, patient stratification, and therapeutic targeting. However, challenges related to data integration, interpretability, and cohort diversity must be addressed to realize this potential. This review underscores the transformative role of machine learning-enhanced multi-omics in reshaping liver cancer diagnosis and treatment and outlines future directions to bridge the gap between computational advances and clinical application.


  • Open Access

    Predicting DNA Methylation state of CpG Islands Using Machine Learning

    by Esraa Mamdouh Hashem, Asmaa Kamal, Mai S. Mabrouk, Mohamed W. Fakhre

    DNA methylation is the primary and best understood epigenetic element that controls human health. It is an essential regulator of gene transcription. Methylation may be the head of some diseases like Parkinson's, cardiovascular, chronic kidney, cancer, and Alzheimer's. The implementation of models to predict DNA methylation has been concentrated by researchers in the bioinformatics area, according to the difficulties of predicting the methylation that is very sensitive to lifestyle or pollution changes. Recent improvements in methylation sequencing way permit the recognition of genome-wide methylated sites in DNA. In the represented work, computational methods are used to predict the methylation of DNA for every CpG locus and non-CpG locus in the whole genome, utilizing Illumina 450K array data within the 250bp region around every CpG site of the human embryonic stem cell with three classifiers including logistic regression, support vector machine, and random forest. The proposed classifiers have been evaluated. Results show that the best performance criteria came from the random forest approach giving an accuracy of 99.9% for a methylation status compared to the other two classifiers. Expressing more features will lead to higher prediction performance and wider detection coverage for methylation of CpG loci.


  • Blood Bank Management System with Mobile Application in Egypt

    by Esraa Mamdouh Hashem, Arwa Bahaa Eldin, Diaa El Din Moatasim

  • Open Access

    Integrative software design for Hospital Information Systems

    by Esraa M. Hashem, Mahmoud F. Y. Shalaby, Mai S. Mabrouk, Samir.Y. Marzouk

    The Hospital Information System is a huge, integrated system that meets these needs. The primary objective of any hospital information system is to produce high-quality and timely reporting for evidence-based decisions and interventions. The electronic health record is essential in creating uniform data formats and terminology for both corporate and public sector reporting needs. In this study, we design a hospital information system that focuses on the tools, and techniques necessary to improve the gathering, archiving, retrieval, and application of information in biomedicine and the healthcare industry. With the intention of bringing about progress, the idea of a paperless hospital is presented as the embodiment of future health information systems. The outcomes of this study succeeded in proposing an integrative system for hospital information, that has the ability to enhance the capability of medical professionals to coordinate patient care.


  • Protein-Ligand In- Silico Molecular Docking Model for Discovering Potential Drugs of COVID-19

    by Esraa Mamdouh Hashem, Mai S. Mabrouk

    The novel human coronavirus is known as SARS-CoV-2, first noticed in late 2019 in Wuhan, China causing a respiratory disease known as COVID-19. This disease has extended rapidly around the world, leading to neuroma deaths and economic losses across many countries. There is currently no approved therapeutics, and effective treatment alternatives remain extremely limited; treating is a pressing need. This work aims to find a potential drug candidate by finding the effective binding between a small molecule (ligand) and a protein by applying protein-ligand docking for target 6YNQ Main protease (Mpro) protein using the AutoDock Vina technique. Several compounds have been identified from the in-silico docking model that could prove effective inhibitors for SARS-CoV-2. Among those compounds and related drugs, 5 best compounds were selected, which had a better score and lower root-mean-square deviation as compared to the reference molecule as: 1.067 Å, 1.78 Å, 1.648 Å, 1.533 Å, and0.027 Å. Results revealed that the identified compounds and drugs (Nintedanib, Nifedipine, NNRTI, and Bordetella pertussis toxoid antigen) are recommended for therapeutic development against the virus as these novel molecules may be utilized to advance innovation and development of antiviral compounds among Coronavirus.